V Mijatovic1, E Florijn, N Halim, R Schats, P Hompes. 1. Department of Reproductive Medicine, Endometriosis Center VUmc, De Boelelaan 1117, 1081 HVAmsterdam, The Netherlands. mijatovic@vumc.nl
Abstract
OBJECTIVES: To establish the effect of adenomyosis on IVF/ICSI outcomes in infertile patients with endometriosis who were pretreated with long-term (>/=3 months) GnRH-agonist prior to IVF/ICSI. STUDY DESIGN: Retrospective study in 74 infertile patients with surgically proven endometriosis who were treated with IVF/ICSI between January 2002 and March 2007. The diagnosis of adenomyosis was based on transvaginal ultrasound criteria. All patients were pretreated with long-term (>or=3 months) GnRH-agonist prior to IVF/ICSI. RESULTS: 90.4% of the patients were diagnosed with endometriosis rASRM stages III-IV. Adenomyosis was demonstrated in 27% of them and was predominantly located in the posterior wall of the uterus. The following IVF/ICSI outcomes were found: a mean duration of GnRH-agonist use prior to IVF/ICSI of 5.35 months (3-26); a mean dosage of FSH used of 208IU (75-450); the mean number of oocytes retrieved was 8.73 (1-30); the mean number of embryos obtained was 3.86 (0-16); the mean number of embryos transferred was 1.6; a mean fertilization rate of 43.6%; a mean implantation rate of 26.3%; a mean miscarriage rate of 24.3%; and a clinical pregnancy rate (fetal heart activity on ultrasound beyond 12 weeks of gestation) of 31.7%. No significant differences were found for any of the IVF/ICSI outcomes between women with and without adenomyosis. CONCLUSIONS: Adenomyosis had no adverse effects on IVF/ICSI outcomes in infertile women with proven endometriosis who were pretreated with long-term GnRH-agonist. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
OBJECTIVES: To establish the effect of adenomyosis on IVF/ICSI outcomes in infertilepatients with endometriosis who were pretreated with long-term (>/=3 months) GnRH-agonist prior to IVF/ICSI. STUDY DESIGN: Retrospective study in 74 infertilepatients with surgically proven endometriosis who were treated with IVF/ICSI between January 2002 and March 2007. The diagnosis of adenomyosis was based on transvaginal ultrasound criteria. All patients were pretreated with long-term (>or=3 months) GnRH-agonist prior to IVF/ICSI. RESULTS: 90.4% of the patients were diagnosed with endometriosis rASRM stages III-IV. Adenomyosis was demonstrated in 27% of them and was predominantly located in the posterior wall of the uterus. The following IVF/ICSI outcomes were found: a mean duration of GnRH-agonist use prior to IVF/ICSI of 5.35 months (3-26); a mean dosage of FSH used of 208IU (75-450); the mean number of oocytes retrieved was 8.73 (1-30); the mean number of embryos obtained was 3.86 (0-16); the mean number of embryos transferred was 1.6; a mean fertilization rate of 43.6%; a mean implantation rate of 26.3%; a mean miscarriage rate of 24.3%; and a clinical pregnancy rate (fetal heart activity on ultrasound beyond 12 weeks of gestation) of 31.7%. No significant differences were found for any of the IVF/ICSI outcomes between women with and without adenomyosis. CONCLUSIONS:Adenomyosis had no adverse effects on IVF/ICSI outcomes in infertilewomen with proven endometriosis who were pretreated with long-term GnRH-agonist. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
Authors: Marissa J Harmsen; Caroline F C Wong; Velja Mijatovic; Arjan W Griffioen; Freek Groenman; Wouter J K Hehenkamp; Judith A F Huirne Journal: Hum Reprod Update Date: 2019-09-11 Impact factor: 15.610
Authors: J M Puente; A Fabris; J Patel; A Patel; M Cerrillo; A Requena; J A Garcia-Velasco Journal: Reprod Biol Endocrinol Date: 2016-09-20 Impact factor: 5.211